June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Yaari, S.

PF287 MIDOSTAURIN IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IS SAFE AND ASSOCIATED WITH IMPROVED REMISSION AND HIGHER TRANSPLANT RATES IN REMISSION - A MULTI-CENTER HISTORICAL CONTROL STUDY

Berger, T.; Rozovski, U.; Moshe, Y.; More

HemaSphere. 3(S1):95, June 2019.

Author:
Yablokova, V.

PS1457 MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3(S1):670-671, June 2019.

Author:
Yachnakis, E.
Author:
Yacobovich, J.
Author:
Yacoub, A.

PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS

Pemmaraju, N.; Ali, H.; Gupta, V.; More

HemaSphere. 3(S1):286-287, June 2019.

PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

Patnaik, M.; Ali, H.; Gupta, V.; More

HemaSphere. 3(S1):289, June 2019.

PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

Rummel, M.J.; Andorsky, D.J.; Coleman, M.; More

HemaSphere. 3(S1):572, June 2019.

Author:
Yagci, N.
Author:
Yagi, H.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Yagüe, J.

PS1214 INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4–1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19+ RELAPSED / REFRACTORY MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Cardozo, C.; More

HemaSphere. 3(S1):553-554, June 2019.

S1636 FRACTIONATED DOSING OF ARI-0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES

Ortiz-Maldonado, V.; Alonso-Saladrigues, A.; Caballero-Baños, M.; More

HemaSphere. 3(S1):756, June 2019.

Author:
Yagurinoski, M.
Author:
Yahalom, V.

PB1825 NIVOLUMAB IN B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSICAL HODGKIN LYMPHOMA

Yakimovich, K.P.; Mikhailova, N.B.; Lepik, K.V.; More

HemaSphere. 3(S1):835-836, June 2019.

Author:
Yakouben, K.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

Author:
Yakushijin, Y.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

Author:
Yamagata, K.
Author:
Yamagishi, M.
Author:
Yamaguchi, J.

PS1354 MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION

Kuwahara-Ota, S.; Shimura, Y.; Isa, R.; More

HemaSphere. 3(S1):619, June 2019.

Author:
Yamaguchi, K.
Author:
Yamakawa, T.

PB2339 GASTROINTESTINAL BLEEDING WAS ASSOCIATED WITH WORSE SURVIVAL IN PATIENTS WITH GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE: SINGLE CENTER RETROSPECTIVE STUDY

Harada, S.; Minauchi, K.; Senjo, H.; More

HemaSphere. 3(S1):1042-1043, June 2019.

Author:
Yamamoto, C.

PF781 FATTY ACID OXIDATION AND MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION REGULATE T-CELL EFFECTOR FUNCTION DURING GRAFT-VERSUS-HOST DISEASE

Nakano, H.; Sato, K.; Hayakawa, H.; More

HemaSphere. 3(S1):344-345, June 2019.

PF784 COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3(S1):345-346, June 2019.

Author:
Yamamoto, K.

PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA

Ogura, M.; Yamamoto, K.; Morishima, Y.; More

HemaSphere. 3(S1):575-576, June 2019.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Yamamoto, M.
Author:
Yamamoto, S.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.

Author:
Yamamoto, T.
Author:
Yamamura, J.
Author:
Yaman Bajin, I.
Author:
Yamane, T.
Author:
Yamasaki, R.

PF781 FATTY ACID OXIDATION AND MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION REGULATE T-CELL EFFECTOR FUNCTION DURING GRAFT-VERSUS-HOST DISEASE

Nakano, H.; Sato, K.; Hayakawa, H.; More

HemaSphere. 3(S1):344-345, June 2019.

PF784 COMPARISON OF ALEMTUZUMAB, ANTI-THYMOCYTE GLOBULIN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE GRAFT-VS-HOST DISEASE AND GRAFT-VS-LEUKEMIA EFFECT IN XENOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Mashima, K.; Oh, I.; Fujiwara, K.; More

HemaSphere. 3(S1):345-346, June 2019.

Author:
Yamashita, S.
Author:
Yan, D.
Author:
Yan, J.L.
Author:
Yan, Y.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3(S1):370, June 2019.

S868 EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

Bannerji, R.; Arnason, J.; Advani, R.; More

HemaSphere. 3(S1):388-389, June 2019.

Author:
Yañez, L.

PB2350 EFFICACY AND SAFETY OF POST HEMATOPOIETIC STEM CELL TRANSPLANTATION DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH ACUTE LEUKEMIA. RETROSPECTIVE ANALYSIS IN OUR CENTER

Romero, Y. Gonzalez; Mora, J.; Cortes, M. A.; More

HemaSphere. 3(S1):1047, June 2019.

Author:
Yang, C.
Author:
Yang, C.-M.

PF805 INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3(S1):355, June 2019.

Author:
Yang, D.-H.

PS956 A MULTICENTER, RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Lee, S.-S.; Jung, S.-H.; Heo, M.H.; More

HemaSphere. 3(S1):430-431, June 2019.

S1613 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA

Kim, T.; Ahn, J.-S.; Jung, S.-H.; More

HemaSphere. 3(S1):743-744, June 2019.

Author:
Yang, D.H.
Author:
Yang, G.

PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Castillo, J.; Abeykoon, J.; Gustine, J.; More

HemaSphere. 3(S1):194-195, June 2019.

Author:
Yang, H.

PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Moreau, P.; Stewart, A.K.; Dimopoulos, M.-A.; More

HemaSphere. 3(S1):260, June 2019.

PS1159 POOLED ANALYSIS OF SAFETY DATA FROM MONOTHERAPY STUDIES OF THE BRUTON TYROSINE KINASE (BTK) INHIBITOR, ZANUBRUTINIB (BGB-3111), IN B-CELL MALIGNANCIES

Tam, C.S.; Opat, S.; Zhu, J.; More

HemaSphere. 3(S1):526, June 2019.

PS1325 IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

Wei, Y.; Class, C.; Kanagal-Shamanna, R.; More

HemaSphere. 3(S1):605, June 2019.

Author:
Yang, J.

PF269 FT-2102, AN IDH1 M INHIBITOR, COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS): RESULTS FROM A PHASE 1 STUDY

Cortes, J.E.; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):86-87, June 2019.

PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY

Montes De Oca, R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3(S1):231, June 2019.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Botton, S. De; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):475-476, June 2019.

PS1247 EZH2 GAIN-OF-FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A PRELIMINARY ANALYSIS ON 590 PATIENTS

Bödör, C.; Batlevi, C.; Nagy, N.; More

HemaSphere. 3(S1):568-569, June 2019.

S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

Palomba, M.L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3(S1):755, June 2019.

Author:
Yang, L.

S109 TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE NEGATIVE RESPONSES AFTER LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

Siddiqi, T.; Dorritie, K.; Soumerai, J.; More

HemaSphere. 3(S1):6-7, June 2019.

Author:
Yang, L.-H.

PF805 INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3(S1):355, June 2019.